特集: 調査項目の変更・追加が可能なセミカスタムオーダー型の調査レポート(Lucintel社)はこちら

特集 : 国別の市場調査レポートをお探しの方はこちら

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界のカポジ肉腫市場:成長、動向、および予測

Kaposi Sarcoma Market - Growth, Trends, and Forecast (2020 - 2025)

発行 Mordor Intelligence LLP 商品コード 922000
出版日 ページ情報 英文 111 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.13円で換算しております。
世界のカポジ肉腫市場:成長、動向、および予測 Kaposi Sarcoma Market - Growth, Trends, and Forecast (2020 - 2025)
出版日: 2020年01月01日 ページ情報: 英文 111 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

当レポートは世界のカポジ肉腫市場について調査しており、市場機会や動向、成長および阻害要因、タイプ・製品・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • HIV関連のカポジ肉腫発生率の増加
    • 臓器移植処置を受けている患者の増加
  • 市場阻害要因
    • カポジ肉腫の治療と診断の高いコスト
    • 広範な需要と供給のギャップによる薬剤の供給不足
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • タイプ別
    • 流行性(エイズ関連)カポジ肉腫
    • 古典的(地中海)カポジ肉腫
    • 風土病型(アフリカ)カポジ肉腫
    • 医原性(移植関連)カポジ肉腫
  • 製品別
    • 診断別
    • 治療別
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Merck & Co., Inc.
    • Celgene Corporation
    • Eli Lilly and Company
    • Navidea Biopharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb
    • Pfizer Inc.

第7章 市場機会および今後の動向

目次
Product Code: 67475

Market Overview

The growing prevalence of the Kaposi Sarcoma and the rising number of patients undergoing organ transplantation procedures as patients undergoing organ transplantations are more susceptible for Kaposi sarcoma, are the major factor attributing the growth of the Kaposi sarcoma market. According to Global Observatory On Donation And Transplantation, 1,39,024 organs were transplanted globally in 2017. Where 90,306 (Kidney), 32,348 (Liver), 7,881 (Heart), 6,084 (Lung), 2,243 (Pancreas), 162 (Small Bowel) transplantations took place. Moreover, the promising number of pipeline studies, growing incidence of HIV-associated Kaposi sarcoma is also a major factor driving Kaposi sarcoma market. However, a shortage in supply of drugs due to a wide demand-supply gap, lack of awareness about this type of cancer, high cost of the treatment and diagnosis of Kaposi sarcoma will impede the growth of the market studied globally.

Scope of the Report

As per the American Cancer Society, "Kaposi sarcoma (KS) is cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but these tumors can also develop in other parts of the body, such as in the lymph nodes (bean-sized collections of immune cells throughout the body), the lungs, or digestive tract". KS is caused by a virus called human herpes virus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpes virus (KSHV).

Key Market Trends

Highly Active Antiretroviral Therapy (HAART) Segment Holds Significant Market Share

  • Kaposi sarcoma (KS) is common cancer associated with the HIV infection and it is considered as an AIDS-defining condition by the US Centers for Disease Control Guidelines.
  • Numerous advancements in the treatment of AIDS-related Kaposi sarcoma have been attained over the last few years, but the introduction of highly active antiretroviral therapy (HAART) has declined the incidences of AIDS-defining illnesses, including KS.
  • For individuals with Epidemic (AIDS-associated) Kaposi sarcoma, antiretroviral treatment for HIV/AIDS is generally used prior to any other therapies for treating the tumor and to reduce the symptoms. HAART might be given as individual therapy or in the combination with chemotherapy depending on the spread of the disease and the patient's symptoms.
  • Seldom, HAART might worsen the condition of the Kaposi sarcoma and the pre-existing infections which leads to a condition called immune reconstitution inflammatory syndrome (IRIS).

North America holds the Largest Market Share in Global Kaposi Sarcoma Market

North America region holds a major market share in the Kaposi treatment market globally. Major factors contributing to this position are the increasing number of product approvals, the presence of many numbers of market players in the market, a high number of R&D initiatives undergoing the treatment and the diagnosis of the Kaposi sarcoma. Additionally, the increasing prevalence of Kaposi sarcoma and HIV is also bolstering the market growth in the region. For instance, According to the American Cancer Society's (ACS) publication, about 1 in 200 transplant recipients in the United States develops Kaposi sarcoma.

Competitive Landscape

Kaposi Sarcoma market has rapidly progressed over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. For instance, in May 2019, The USFDA granted breakthrough therapy designation to Celgene's pomalidomide (Pomalyst) for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Incidence of HIV-Associated Kaposi Sarcoma
    • 4.2.2 Rising Number of Patients Undergoing Organ Transplantation Procedures
  • 4.3 Market Restraints
    • 4.3.1 High Cost Of The Treatment And Diagnosis Of Kaposi Sarcoma
    • 4.3.2 Shortage In Supply Of Drugs Due To Wide Demand-Supply Gap
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type
    • 5.1.1 Epidemic (AIDS-associated) Kaposi sarcoma
    • 5.1.2 Classic (Mediterranean) Kaposi sarcoma
    • 5.1.3 Endemic (African) Kaposi sarcoma
    • 5.1.4 Latrogenic (transplant-related) Kaposi sarcoma
  • 5.2 By Product
    • 5.2.1 By Diagnostics
      • 5.2.1.1 Biopsy
      • 5.2.1.2 Bronchoscopy
      • 5.2.1.3 Gastrointestinal endoscopy
      • 5.2.1.4 Others
    • 5.2.2 By Treatment
      • 5.2.2.1 Highly Active Antiretroviral Therapy (HAART)
      • 5.2.2.2 Radiation Therapy
      • 5.2.2.3 Chemotherapy
      • 5.2.2.4 Immunotherapy
      • 5.2.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co., Inc.
    • 6.1.2 Celgene Corporation
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 Navidea Biopharmaceuticals, Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Bristol-Myers Squibb
    • 6.1.7 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS